CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma

Patients with relapsed and/or refractory (R/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R/R F...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohty, Razan, Kharfan-Dabaja, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761215/
https://www.ncbi.nlm.nih.gov/pubmed/36544864
http://dx.doi.org/10.1177/20406207221142133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761215/
https://www.ncbi.nlm.nih.gov/pubmed/36544864
http://dx.doi.org/10.1177/20406207221142133

Ejemplares similares